• Bolder BioTechnology Inc., of Boulder, Colo., published a study showing that its long-acting inerleukin-11 analogue prevented kidney damage from ischemia reperfusion injury in mice. The research was carried out at Columbia University, and published online in the American Journal of Physiology.